Electromed, Inc.

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy systems used to help patients with compromised pulmonary function clear mucus and breathe more easily. Its core product is the SmartVest® Airway Clearance System, sold mainly through a direct-to-patient and provider model that works with clinicians, manages insurance reimbursement, and delivers devices for home use, with additional sales into hospitals and selected international markets.

20,0 %

78,5 %

15,3 %

+15,3 %

4.69

4.39

— Electromed, Inc.
%
Airway clearance systems88% HFCWO devices that help mobilize secretions and improve bronchial drainage.
Homecare services and support7% Patient onboarding, training, insurance claims support, and direct fulfillment for home use.
Hospital and acute-care sales5% Device sales for inpatient, post-surgical, ICU, and respiratory therapy settings.

Electromed sells primarily to patients with physician prescriptions, but the buying process is driven by...

  • Homecare patients with pulmonary diseaseprimary

    Patients with bronchiectasis, cystic fibrosis, COPD-related bronchiectasis, and chronic pulmonary conditions who use SmartVest at home because it is prescribed, reimbursable, and supported by direct delivery and training.

  • Neuromuscular disease patientsprimary

    Patients with ALS, cerebral palsy, muscular dystrophies, and similar conditions who need airway clearance to manage retained secretions and reduce respiratory complications.

  • Pulmonologists and referring cliniciansprimary

    Specialists and clinic staff who identify eligible patients, prescribe therapy, and influence adoption through clinical confidence and referral patterns.

  • Hospitals and acute-care institutionssecondary

    Hospitals, rental companies, and other institutions purchasing HFCWO systems for inpatient, post-surgical, ICU, or infection-related respiratory support.

  • HME and respiratory therapy distributorssecondary

    Limited distribution partners that extend reach in the U.S. homecare market and support incremental sales volume.

Electromed is primarily a U.S. business, and management says most revenue comes from domestic homecare sales through...

  • •U.S. is the core market and the main source of revenue
  • •Domestic homecare is the largest channel and depends on referrals
  • •U.S. hospital sales add a smaller acute-care revenue stream
  • •Select international countries are served through approvals and distributors
  • •International distributor demand is smaller and more volatile

Electromed is focused on expanding its direct sales force, increasing awareness of HFCWO therapy, and growing share in...

01
Expand the direct sales forceshort-term

More territories and reps should increase referrals, approvals, and homecare conversions.

02
Increase share in adult pulmonology and bronchiectasismedium-term

This is described as the largest and fastest-growing addressable segment.

03
Improve product innovation and patient experiencemedium-term

Better usability and comfort can support conversion, retention, and clinician preference.

Electromed depends on physician referrals, insurance reimbursement, and continued clinical acceptance of HFCWO therapy,...

high

Insurance reimbursement and coverage risk

The SmartVest System often relies on Medicare, Medicaid, HMOs, and private payer approval for adoption.

Scope
Homecare sales and patient conversion
Materiality
high
high

Physician referral and clinical adoption risk

The direct-to-patient model depends on pulmonologists and clinicians prescribing therapy and supporting referrals.

Scope
Core domestic revenue engine
Materiality
high
high

Regulatory and product clearance risk

The company depends on FDA clearance and ongoing compliance for marketed devices.

Scope
Product portfolio and future launches
Materiality
high
medium

Hospital capital spending cyclicality

Hospital revenue can fluctuate with capital budget allocations and long sales cycles.

Scope
Hospital and acute-care segment
Materiality
medium
medium

Channel mix and distributor execution risk

Limited HME and international distributor sales can be uneven and depend on partner performance.

Scope
Homecare distributor and other revenue
Materiality
medium
Revenue recognition
Affects reported revenue by channel and quarterly comparability
Quarterly seasonality and lumpy hospital demand
Can distort near-term growth rates and margin trends
Share-based compensation valuation
Affects SG&A and diluted earnings

electroCore, Inc.

ECOR · Electromedical & Electrotherapeutic Apparatus

TACTILE SYSTEMS TECHNOLOGY INC

TCMD · Surgical & Medical Instruments & Apparatus

Pulmonx Corp

LUNG · Surgical & Medical Instruments & Apparatus

IR-Med, Inc.

Electromedical & Electrotherapeutic Apparatus

Streamex Corp.

STEX · Electromedical & Electrotherapeutic Apparatus

CONMED Corp

CNMD · Electromedical & Electrotherapeutic Apparatus

: 28/04/2026